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Abstract  
Introduction: Scaling up of antiretroviral therapy (ART) to HIV+ pregnant women is crucial for the elimination of HIV infection in children. The 
aim of this study was to evaluate the feasibility and effectiveness of triple ART for Prevention of Mother-to Child Transmission (PMTCT) in 
Cameroon. Methods: HIV-positive pregnant women attending the DREAM Centre of Dschang, Cameroon for prenatal care were enrolled in a 
prospective cohort study, and received ART until the end of breastfeeding or indefinitely if their CD4 count was <350mm3. Infants were evaluated 
for HIV infection at 1, 6 and 12 months of age. Results: A total of 298 women were enrolled. Among them, 152 were already on established ART. 
Women were followed until 6 months after delivery with a retention rate of 92.6%. Eight women died. Those with a CD4 count <350 
cells/mm3 during pregnancy had the highest mortality risk (RR 2.53; 95% CL= 1.86-3.44). The HIV transmission rate was 1.2% at 12 months with 
an HIV free survival of 91%. In the proportional Cox regression analysis, the following factors were positively associated with infant mortality: 
maternal CD4< 350 cells/mm3, no breastfeeding in the first 6 months of life, weight-for-age z score < -2. Conclusion: Results confirm the 
feasibility and effectiveness of the implementation of Option B, with very low rates of HIV MTC transmission, and potential benefits to the health of 
mothers and infants with earlier initiation of ART. Breastfeeding again demonstrates to be highly beneficial for the growth and survival of HIV 
exposed children. 
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Introduction 
 
It is well known that administration of triple antiretroviral therapy 
(ART) to HIV infected women during pregnancy and breastfeeding 
can reduce HIV mother to child (MTC) transmission to less than 5% 
[1-4]. In Sub-Saharan Africa, the use of ART for prevention of MTC 
transmission (PMTCT) has been limited until recent years with 
various single drug regimens and short course dual antiretroviral 
regimens applied. In 2013, the WHO endorsed the use of lifelong 
ART (Option B+) or ART until at least the end of breastfeeding 
(Option B) for HIV PMTCT [5]. Many challenges remain in sub 
Saharan African countries in order to achieve the goal of elimination 
of MTC transmission: insufficient access of pregnant women to HIV 
testing and treatment, poor implementation of PMTCT programs, 
and insufficient levels of retention in care [6-8]. Cameroon is among 
the 22 priority countries for the elimination of HIV mother-to child 
transmission. HIV+ rates among pregnant women have been 
estimated at 7.8% at a national level [9]. Cameroon is implementing 
since 2012 a gradual shift to Option B+ strategy for prevention of 
MTC transmission. There are few studies in Cameroon describing 
the use of triple ART for PMTCT [10, 11]. Nutritional strategies are 
also very important in order to guarantee a better chance of survival 
to HIV exposed children. Some studies show that children born to 
HIV infected mothers often have a higher mortality than children 
born to uninfected mothers, and worse nutritional status [12-14]. In 
HIV exposed uninfected children, this is partially due to suboptimal 
feeding strategies. The effectiveness of ART in reducing postnatal 
transmission through breastfeeding has to a large extent resolved 
the dilemma of how HIV-infected mothers should feed their infants. 
Some studies report reductions in mortality in association with 
breastfeeding in HIV exposed uninfected infants [15]. DREAM is a 
program of care for people with HIV designed and managed by the 
Community of Sant'Egidio, which is now working in ten African 
countries including Cameroon. The DREAM program offers free of 
charge state-of-the-art treatment, diagnostic facilities and nutritional 
supplementation to patients. The DREAM programme has been 
implementing PMTCT with triple antiretroviral therapy since 2004 in 
Mozambique and Malawi [16, 17]. In 2008 we proposed to the 
Ministry of Health of Cameroon the implementation of a study to 
evaluate the feasibility and outcomes of Option B implementation in 
the district of Dschang, a mixed urban/rural area in the western 
region of the country. Results are helpful in the planning and 
implementation of further scaling up. The proposal was accepted in 
2009 under the framework of an operational research project 
approved by the Ministry of Health. The aim of the present study 
was to evaluate HIV transmission rates, as well as infant and 
maternal mortality, retention in care, and HIV-free infant survival. 





Study design: prospective cohort study. 
  
Study setting: the study was conducted at the DREAM Centre, 
Hospital St Vincent de Paul, Dschang, West Region, Cameroon. 
  
Population: the study population included all HIV-positive 
pregnant women attending the DREAM Centre in Dschang from 
September 2009 to September 2011. Women were referred from 
the surrounding antenatal care (ANC) centres, or self-referred as 
seeking care for HIV. 
  
Procedures and measurements: pregnant women already on 
established ART at presentation continued on treatment. Women 
not on ART initiated lifelong ART as soon as the 14th week of 
gestational age was reached if they had a CD4 count of less than 
350 cells/mm3. Women presenting with a CD4 count greater than 
350 cells/mm3initiated ART at 25 weeks of gestational age, and 
discontinued ART after 6 months postpartum. Women were 
counselled to exclusively breastfeed, to introduce complementary 
food when the child reached 5 months of age, and to wean the child 
at the age of 6 months. Women, who did not want/could not 
breastfeed, were counselled to give exclusive formula milk until 6 
months of age. ART regimens consisted primarily of: 
Zidovudine+Lamivudine+Nevirapine (AZT+3TC+NVP) or 
Stavudine+Lamivudine+Nevirapine(D4T+3TC+NVP), the main first 
line regimens used at that time in the country. Women who 
experienced NVP-related reactions were shifted to a regimen 
containing Lopinavir/Ritonavir. Women were offered: monthly health 
checks, weight and height measurements, adherence counselling, 
medical visits, CD4 counts every 6 months, baseline and yearly viral 
load (VL) monitoring, pre-ART and routine whole blood count and 
biochemistry, nutritional counselling and supplementation 
depending on nutritional status. Infants were offered: single dose 
Nevirapine at birth, monthly checks, weight, length/height and arm 
circumference measurements, medical visits, and were evaluated for 
HIV infection by branched DNA assay at 1 and 6 months of age. At 
12 months a rapid test was performed, and if positive a virological 
test was performed. A rapid HIV test was performed also at 18 
months of age. Height and weight were measured according to 
standard anthropometric methods and z scores were calculated with 
the software "ANTHRO" having as reference the WHO Child Growth 
Standards 2006 [18]. Underweight was defined as having a weight 
for age z score (WAZ)<-2 and stunting as having a length-for-age z 
score (LAZ)<-2. Women or children not presenting to the scheduled 
appointments were called by the staff. Women and children not 
returning after 3 months were considered lost to follow up. Women 
asking a note of transfer for another facility were registered as 
transferred. 
  
Statistical analysis: descriptive data are presented as means with 
standard deviations (SD), or median and IQ ranges. Differences 
between means were tested with the Student t test. Categorical 
data were compared using the chi-square test or the Fisher test as 
appropriate. The Kaplan-Meier method was used to estimate the 
rates of child survival (including HIV-free survival) and Cox 
proportional hazards model was used to identify factors associated 
with mortality in children. For all statistical tests, two sided P values 
of less than 0.05 were considered to be statistically significant. For 
women, data were censored at 6 months after delivery and for 
children at 12 months of age. SPSS v. Win 18.0 was used for data 
analysis. 
  
Ethics statement: the study was approved by the National Ethic 
Committee (133/CNE/SE/09) and authorized by the Ministry of 






Study participant characteristics: a total of 298 women were 
enrolled in the study over the two year period. Among them, 152 
were already on established ART. Of 146 pregnant women who 
initiated ART during pregnancy, 81 (55.5%) had a CD4 count>350 
cells/mm3. The mean age was 30.24±5.4 years. The main clinical 
data and the cohort profile are summarized in Table 1 and Figure 
1. At the time of counselling, 70% of women reported knowledge of 
the serological status of their partner. 
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Maternal outcomes: at the censoring time point (6 months after 
delivery), 8 women (2.6%) had died, 11 (3.7%) had abandoned the 
programme, 3 had been transferred to other facilities due to 
proximity reasons, and 276 (92.6%) had completed the protocol. 
LTFU rates were 5.5% for women presenting to care during 
pregnancy and 2% for women on established ART prior to 
pregnancy. Seven of the 8 maternal death occurred in women with 
a CD4 count of less than 350 cells/mm3 (RR 2.53; 95% CL= 1.86-
3.44). Two hundred seventy five living infants were born (including 
twins). Only 3.6% of women delivered at home, 73.1% delivered at 
the hospital and 22.9% at a health centre facility. The median 
duration of ART before delivery was 94 days (IQR 65.5-110) for 
women initiating ART in pregnancy, and 801 days (IQR 567-1110) 
for women already on established ART. We observed 13 abortions 
and 10 stillbirths (Table 1). 
  
Mother-to-child HIV transmission: HIV status was available for 
265 of 275 infants (96.3%) at one month of age, and for 242 
infants at 12 months of age (88% of the original cohort). At 12 
months, 3 infants had acquired HIV, corresponding to a 
transmission rate of 1.2%. The HIV transmission rate was 1.5% 
among children born to women who initiated ART in pregnancy, and 
0.8% among women on established ART (difference not statistically 
significant, p=0.53). One infant was found to be infected at one 
month, one at 6 months and one at 12 months of age. The three 
children at the censoring date were receiving ART and in good 
health. The infant cohort profile is shown in Figure 2. LTFU rates 
among children were 5 per 100 person years. Eight of 11 LTFU 
happened after six months of age. 
  
Child growth and survival: forty-five infants(17%)out of 275 
were born with a birth weight of less than 2.5 kg. A positive 
correlation was observed between birth weight and length of ART in 
mothers before delivery: women in the lowest quartile of duration of 
ART gave birth to children with a birthweight slightly lower than 
women in the highest quartile of ART duration (2.8±0.56 kg against 
3.0±0.55 kg; p=0.023). Eighty-nine percent of infants (243 out of 
272 for whom the information was available) were exclusively 
breastfed until 5 months of life. Mean WAZ and LAZ are summarized 
in Figure 3. Twenty-two infants died before one year of age, 
corresponding to an infant mortality of 80 per 1000 (neonatal 
mortality of 29 per 1000, post neonatal of 51 per 1000) (Figure 4). 
HIV-free survival was 91% at 12 months. In the proportional Cox 
regression analysis, the following factors were positively associated 
with infant mortality (Table 2): maternal CD4 < 350 cells/mm3, no 
breastfeeding in the first 6 months of life, WAZ<-2 at any time from 





The present study reports our results regarding the feasibility and 
the effectiveness of triple ART for HIV PMTCT in pregnant women 
followed in DREAM Centre in Cameroon. We included both women 
starting ART during pregnancy and women already on established 
ART who became pregnant. As countries are expanding access to 
ART and moving to Option B+, there will be an increasing number 
of women in this last situation. In our cohort, women on established 
therapy had better clinical and laboratory values (in terms of 
haemoglobin levels and nutritional conditions) as compared to 
women starting ART during pregnancy, regardless of CD4 cell count, 
and relatively high CD4 values overall (mean 460±165). HIV 
transmission rates were extremely low in the established therapy 
group (0.8% at 12 months of age) even if no statistical difference 
emerged when comparing both groups of mothers. The significantly 
and substantially higher level of mortality observed in women with a 
CD4 cell count of less than 350 cells/mm3 during pregnancy (RR 
2.53; 95% CL= 1.86-3.44) is an important confirmation that 
implementation of the new criteria of WHO Consolidated Guidelines 
[5] (initiation of treatment in pregnancy irrespective of CD4 cell 
count or initiation of treatment at a CD4 cell count < 500) is a key 
strategy not only for prevention of HIV in infants, but also as a 
strategy for optimization of maternal survival. The maternal 
retention rate was 92.6% six months after delivery, including 
deaths, LTFU and transfers. Other studies carried out in sub 
Saharan Africa report disengagement from care varying from 30% 
to 50% [19, 20]. Data from the implementation of Option B+ in 
Malawi showed 77% retention after 12 months at a national level 
[21]. Other studies have shown that the highest attrition occurs in 
the first months between testing and linkage to care [22]. The 
service delivery model of the DREAM Centre, with the PMTCT 
program embedded into the ART program, likely has a beneficial 
effect on retention, as shown in some studies [23], although we 
have no information on women lost between testing and linkage to 
care. Other reasons for the high rates of retention observed are 
timely initiation of ART and the active monitoring and adherence 
reinforcement strategy approach of the DREAM Programme, 
previously described [24]. 
  
The proportion of children born with a low birthweight was 17% in 
our study, which is higher than data for the general population in 
Cameroon [25] but comparable to data from other studies of infants 
born to HIV+ mothers in the country [11, 26]. Some past studies 
have expressed concern regarding the potential impact of ART 
treatment on low birth weight [27], especially if PI containing 
regimens are used [28]. Many other authors did not observe such 
correlation [29, 30]. On the other hand, the adverse effects of HIV 
infection of itself on nutritional condition are well known. Although 
we did not perform a comparative analysis between women 
using/not using ART, in our cohort we did not observe an 
association between longer duration of ART and low birth weight. 
On the contrary, women with the longest exposure to ART before 
delivery gave birth to newborns with slightly higher birth weights 
(2.8 Kg vs. 3Kg respectively; p = 0.023). The HIV transmission risk 
in our cohort was very low, and HIV free survival was comparable to 
data obtained in other studies on the effectiveness of maternal triple 
ART in other Sub Saharan countries [31]. A retrospective study 
carried out in Yaoundé on 418 HIV+ pregnant women [11] reported 
HIV transmission rates of 6.6% at 6 weeks. In this study women 
were using different drug regimens, with only 17.5% using a triple 
drug regimen. Another study carried out in Yaoundé with 587 HIV+ 
pregnant women [10], found transmission rates of 1.7% among 
women on triple antiretroviral therapy, comparable to those 
obtained in the present study. Eighty-nine percent of the women 
chose exclusive breastfeeding, this rate is higher if compared to 
data from Yaoundé and Eastern Cameroon [8, 32] and can be 
related both to the rural residency of the population and to the 
effectiveness of counselling, given the updated knowledge of health 
staff on risks and advantages of breastfeeding within the context of 
HIV infection. The nutritional status of children was good, with 
4.6% infants being underweight at 3 months and 1.5% at 6 
months, although a decline in mean WAZ and HAZ was observed 
from 6 to 12 months, the period in which infants were weaned. A 
similar decline has been observed in other studies, particularly when 
infants stop being breastfed [33]. In particular, at 12 months 33.6% 
of children were stunted, which is consistent with observations 
made in another study in the same area [34]. These rates are likely 
to improve with the prolongation of breastfeeding to 12 months, as 
recommended by the WHO [35]. The child mortality in our cohort 
was 80 per 1000. HIV transmission seemed to have a relatively low 
impact on HIV-free survival, as in our cohort all deaths occurred 
among HIV-exposed uninfected infants, although since HIV testing 
was not performed at birth, it is not possible to exclude an 
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association between neonatal mortality and in utero HIV 
transmission. As in other studies [30], maternal baseline CD4 cell 
count of less than350/mm3 was a predictor of infant mortality. Other 
significant predictors in the multivariate analysis were a low weight 
for age score at any age, including birth, and not being breastfed. 
Breastfeeding was shown to be highly beneficial to infant growth 
and survival, as shown in previous studies [36]. Limitations to the 
study include the relatively small sample size of women and 
children, the lack of complete information on adherence, and the 
absence of early HIV testing at birth, which precluded us from 





The study confirmed the feasibility and substantial advantages in 
the implementation of triple antiretroviral therapy for HIV PMTCT in 
Cameroon, not only for effective prevention of HIV vertical 
transmission but also for reduction of maternal mortality. Our 
results indicate that full implementation of the new WHO 
consolidated guidelines for HIV PMTCT will have a very favourable 
outcome in this population. Extending breastfeeding while mothers 
receive ART until at least 12 months of life will likely positively affect 
the nutritional status and reduce mortality among HIV exposed 
infants. 
 
What is known about this topic 
 
• Triple antiretroviral therapy to HIV infected women during 
pregnancy and breastfeeding (Option B, B+) can reduce 
HIV mother to child transmission to less than 5%. 
• Insufficient levels of retention in care are among the 
obstacles for elimination of MTC transmission. 
• HIV exposed infants have worse nutritional status than 
HIV unexposed infants. 
 
What this study adds 
• Experience of option B in Cameroon. 
• Data on clinical and biological parameters on women 
already on ART and having a pregnancy. 
• In this cohort of HIV exposed infants, maternal CD4, 
absence of breastfeeding and low weight for age are 
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Table 1: characteristics of women in the study 
    All A. Initiated ART in 
pregnancy, 
CD4>350/mm3 
B. Initiated ART 
in pregnancy, 
CD4<350/ mm3 





Number   298 81 65 152   
Baseline data Age (years), 
mean±SD 30.2±5.4 29.4±6.3 30.0±5.3 30.8±5 
A vs Bp=0.5 
A vs C p=0.1 
B vs C p=0.3 
  CD4 
(cells/mm3), 
mean±SD 
443±298 578±230 236±87 460±165 
A vs B p<0.001 
A vs C p<0.001 
B vs C p<0.001 
  Haemoglobin 
(g/dl), mean±SD 11.4±1.3 11.2±1.1 10.6±1.2 11.9±1.2 
A vs B p=0.03 
A vs C p<0.001 
B vs C p<0.001 
  CV log 
  2.46±1.8 3.53±1 4.08±0.95 1.23±1.46 
A vs B p=0.002 
A vs C p<0,001 
B vs C p<0,001 
  Arm Circumf. 
(cm), mean±SD 28 ±3.3 28.1±3.2 27±2.9 28.4±3.4 
A vs B p=0.03 
A vs C p=0.4 
B vs C p=0.004 
  BMI, median (IQR) 26.45 (24.17-
29.3) 
26.7 (24.8-29.3) 25.5 (23.3-28.4) 26.7 (24.2-29.5)   
Pregnancy 
outcomes 
No. of Abortions 
13 1 1 11   
  No. of Stillbirths 10 3 3 4   
  No. live births 260 71 57 132   




292 (94-802) 93 (69-104) 105 (64-154) 810 (567-1110)   
  Delivered at 
hospital 
190 55 37 98   
  Delivered at home 10 3 2 5   
  Delivered at health 
centre 
60 14 18 28   
Table 2: hazard risk for mortality in children (cox proportional hazards model, stepwise) 
  Hazard Risk CL 95% P value 
Maternal Cd4 
<350/mm3 
3.8 1.20-8.48 0.021 
Underweight 4.36 1.68-11.28 0.002 
Breastfeeding 0.039 0.13-0.95 0.039 
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Figure 4: Infant survival according to maternal CD4 count 
 
 
